The U.S. Centers for Disease Control and Prevention (CDC) is responding to a major outbreak of Ebola disease caused by the Bundibugyo virus, a relatively rare strain for which no licensed vaccine or specific treatment currently exists.
As of October 20, 2026, the outbreak—centered in the Democratic Republic of the Congo (DRC)—has recorded 9,668 confirmed cases and 4,649 confirmed deaths, making it the second-largest Ebola outbreak on record and the largest ever in the DRC. The virus has also been detected in limited numbers in Uganda, Kenya, Nigeria, and one case in France linked to travel from the DRC. No cases associated with this outbreak have been confirmed in the United States, and the CDC assesses the overall risk to the American public and travelers as low.
The outbreak is caused by Bundibugyo virus (species Orthoebolavirus bundibugyoense), one of four types of Ebola virus known to cause disease in humans. Unlike the more common Zaire ebolavirus, which drove the large 2014–2016 West Africa epidemic and the 2018–2020 DRC outbreak, there is no FDA-approved vaccine specifically targeting Bundibugyo. The licensed vaccine Ervebo (rVSV-ZEBOV), developed against Zaire ebolavirus, is not expected to provide reliable cross-protection based on available animal and laboratory data, according to CDC and World Health Organization (WHO) assessments. Official guidance advises against its routine use outside controlled research settings during Bundibugyo outbreaks.
Treatment similarly remains limited to supportive care—fluids, electrolyte management, oxygen support, and treatment of secondary infections—as no specific antiviral or monoclonal antibody therapy is licensed for this strain. Experimental candidates, including the antibody cocktail MBP134 and the antiviral remdesivir, are being evaluated in clinical trials in the DRC.
Health authorities have begun limited use of the Zaire-targeted Ervebo vaccine under study protocols for frontline health workers in some affected areas, while specific Bundibugyo vaccine candidates from developers including Oxford and Moderna are advancing toward trials. A vaccine trial known as Tumaini (“hope” in Swahili) is expected to evaluate both the mismatched Ervebo and Bundibugyo-specific shots. Efficacy data for new candidates may not be available until early 2027.
The outbreak, first declared in May 2026, has spread substantially faster than previous Ebola epidemics, surpassing 1,000 confirmed cases within 40 days of response activation. Cases have been confirmed across multiple DRC provinces, including Ituri (the epicenter), North Kivu, Haut-Uele, and others. Challenges include limited health infrastructure, ongoing conflict, violence against healthcare workers, and population movement that increases the risk of further regional spread.
CDC continues to monitor the situation closely, support international partners, and maintain domestic preparedness measures, including travel guidance. The agency emphasizes that while the risk of introduction to the United States remains very low, robust public health systems and infection control practices would limit any potential domestic transmission if a case were detected.
Africa Centres for Disease Control and Prevention (Africa CDC) has called for strengthened continental coordination as the outbreak expands geographically, describing it as one of the most widespread Ebola events in history. Officials stress that early detection, contact tracing, isolation, safe burials, and community engagement remain the primary tools for control in the absence of a licensed vaccine for the circulating strain.
About the Author
